UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne

Lourbakos, A; Yau, N; de Bruijn, P; Hiller, M; Kozaczynska, K; Jean-Baptiste, R; Reza, M; ... Spitali, P; + view all (2017) Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. Scientific Reports , 7 , Article 17888. 10.1038/s41598-017-17982-y. Green open access

[img]
Preview
Text (Published article)
s41598-017-17982-y.pdf - ["content_typename_Published version" not defined]

Download (2MB) | Preview
[img]
Preview
Text (Supplementary information)
Lourbakos_Evaluation_serum_MMP-9_Suppl.pdf

Download (637kB) | Preview

Abstract

Duchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin. Predictive biomarkers able to anticipate response to the therapeutic treatments aiming at dystrophin re-expression are lacking. The objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for Duchenne. Two natural history cohorts were studied including 168 longitudinal samples belonging to 66 patients. We further studied 1536 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucleotide targeting exon 51: an open label study including 12 patients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open label extension study performed after the phase 3. Analysis of natural history cohorts showed elevated MMP-9 levels in patients and a significant increase over time in longitudinal samples. MMP-9 decreased in parallel to clinical stabilization in the 12 patients involved in the open label study. The phase 3 study and subsequent extension study clarified that the decrease in MMP-9 levels was not predictive of treatment response. These data do not support the inclusion of serum MMP-9 as predictive biomarker for DMD patients.

Type: Article
Title: Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41598-017-17982-y
Publisher version: http://dx.doi.org/10.1038/s41598-017-17982-y
Language: English
Additional information: Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > UCL GOS Institute of Child Health > ICH Developmental Neurosciences Prog
URI: http://discovery.ucl.ac.uk/id/eprint/10041126
Downloads since deposit
84Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item